WALTHAM, Mass.--(BUSINESS WIRE)--March 31, 2006--Interleukin Genetics, Inc. (AMEX:ILI) today announced changes in its executive management team intended to accelerate development and commercialization of products utilizing its genetic based intellectual property. Kenneth S. Kornman, DDS, Ph.D., founder, President and Chief Scientific Officer of the Company, will assume the additional role of Chief Executive Officer, effective immediately. Dr. Kornman will continue to oversee the relationship with the Company's primary strategic partner, Alticor, to facilitate the launch of genetic tests globally.
